|
33.
|
|
7 p, 434.6 KB |
SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
/
Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ;
Iveson, Timothy (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Kerr, Rachel S. (University of Oxford. Department of Oncology) ;
Saunders, Mark P. (The Christie Hospital) ;
Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Hollander, Niels Henrik (Zealand University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ;
Glimelius, Bengt (University of Uppsala) ;
Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Hughes, Rob (Mount Vernon Cancer Centre) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Olesen, Rene K. (Zealand University Hospital) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (University College London) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ;
Hickish, Tamas (Poole Hospital/Bournemouth University) ;
Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ;
Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 -  10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338
|
|
|
34.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Karthaus, M. (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D. (Bordeaux University Hospital (França)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M. (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B. A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A. S. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, Alberto (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
|
35.
|
|
7 p, 176.2 KB |
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review
/
García-Foncillas, Jesús (Hospital Universitario Fundación Jiménez Díaz) ;
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Díaz-Rubio, Eduardo (Hospital Clínico San Carlos (Madrid)) ;
López López, R. (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of oncology, Vol. 28 (september 2017) , p. 2943-2949
|
|
|
36.
|
|
8 p, 196.5 KB |
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
/
Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ;
Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ;
Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ;
Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ;
Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ;
Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ;
Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ;
Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ;
Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ;
Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485
|
|
|
37.
|
|
8 p, 2.4 MB |
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
/
Tamborero, David (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rubio-Perez, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Deu-Pons, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Schroeder, Michael P. (Charité - Universitätsmedizin Berlin) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Rovira, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Tusquets, Ignasi (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Albanell Mestres, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
De Torres, Carmen (Institut de Recerca Sant Joan de Déu) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Gonzalez-Perez, Abel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. [...]
2018 - 10.1186/s13073-018-0531-8
Genome Medicine, Vol. 10 (March 2018) , art. 25
|
|
|
38.
|
|
8 p, 590.0 KB |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
/
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ;
Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ;
Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Bodoky, G. (St László Hospital (Hongria)) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ;
Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ;
Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609
|
|
|
39.
|
|
11 p, 388.8 KB |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
/
Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ;
Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A. X (Massachusetts General Hospital (Boston)) ;
Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ;
Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942
|
|
|
40.
|
|
7 p, 242.6 KB |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies
/
Boeckx, N. (University Hospital Antwerp (Bèlgica)) ;
Koukakis, R. (Biostatistics, Amgen Ltd) ;
Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ;
Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ;
Van Camp, G. (University Hospital Antwerp (Bèlgica)) ;
Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ;
André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868
|
|
|
41.
|
|
8 p, 357.7 KB |
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
/
Grasselli, Julieta (Institut Català d'Oncologia) ;
Elez, Elena (Universitat Autònoma de Barcelona) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Santos Vivas, Cristina (Institut Català d'Oncologia) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Vidal, J. (Hospital del Mar (Barcelona, Catalunya)) ;
Garcia, M.. (Institut Català d'Oncologia) ;
Viéitez, J. M. (Hospital Universitario Central de Asturias) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Falcó, E. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Lopez Lopez, C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Jones, F. (Sysmex Inostics, Mundelein, USA) ;
Sikri, V (Sysmex Inostics, Mundelein, USA) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Montagut, Clara (Hospital del Mar (Barcelona, Catalunya)) ;
Azuara, D. (Institut Català d'Oncologia) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Salazar, R. (Institut Català d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301
|
|
|
42.
|
|
10 p, 1016.0 KB |
Global cancer control : responding to the growing burden, rising costs and inequalities in access
/
Prager, Gerald W. (Medical University of Vienna) ;
Braga, Sofia (Instituto CUF Oncologia) ;
Bystricky, Branislav (Faculty Hospital Trencin) ;
Qvortrup, Camilla (Odense University Hospital (Dinamarca)) ;
Criscitiello, Carmen (Istituto Europeo di Oncologia) ;
Esin, Ece (Ankara Oncology Education and Research Hospital) ;
Sonke, Gabe S. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ;
Karamouzis, Michalis (National and Kapodistrian University of Athens) ;
Strijbos, Michiel (AZ KLINA Hospitals) ;
Yazici, Ozan (Ankara Numune Education and Research Hospital) ;
Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ;
Banerjee, Susana (Royal Marsden Hospital (Regne Unit)) ;
Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Zielinski, Christoph C. (Medical University Vienna, General Hospital, and Vienna Cancer Center) ;
Casali, Paolo Giovanni (Istituto Nazionale Tumori) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Jezdic, Svetlana (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Bricalli, Gracemarie (European Society for Medical Oncology) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO open, Vol. 3 (february 2018)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
